Conexeu Sciences Inc. is a preclinical-stage regenerative tissue platform company headquartered in Reno, Nevada, with R&D operations in Vancouver. It develops collagen-based extracellular matrix (ECM) technology, branded CXU, that is delivered as a room-temperature flowable liquid and transitions in situ to a gel-like scaffold at body temperature in roughly ten minutes, providing temporary structure for the body to repopulate, remodel and regenerate its own tissue. The technology came out of more than a decade of university research and is being advanced toward wound care first, with a 510(k) premarket notification planned for early 2027. The company began trading on Nasdaq under the ticker CNXU in May 2026.